Touchstone
Last syncNov 1, 2026, 6:55 PM ET

QGEN

Qiagen N.v. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$50.22Close $10.9BMarket cap $32.34 – $55.1652-week range Nov 4, 2026Next report · after the close
Repair to Leader 8th of 18

Highlights

Strengths

  • Accumulation up-day volume 2.1× down-day volume over 50 sessions

Cautions

  • Trend not confirmed 7 of 8 conditions · 150-day under the 200-day
  • Extended 5.4 ATR above its 50-day average
  • Results soon Nov 4, 2026, in 3 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Mar 20, 2026
Off 12-month high 9% 55% above the low
1wk down 0.3% price change
1mo up 14.8% price change
12-month return up 9% market up 11% · its own down 3%
F-score 8 / 9 Exceptional
Altman Z 4.08 Low risk
P/E 25.6× price / earnings
PEG 0.06 P/E / EPS growth
P/B 2.9× price / book
Earnings yield up 4.0% EBIT / enterprise value
Cheaper than 57% of the market · around average
Revenue growth up 6% year on year
EPS growth — latest quarter
Sales growth — latest quarter
ROE up 12% return on equity
Free cash margin up 22% $453.3M FCF
D/E 0.44 long-term debt / equity
Net debt / EBITDA 1.2×
Interest cover —EBIT / interest
Piotroski tests
  • took on more long-term debt
  • profitable on its assets
  • generating cash from operations
  • profitability improving
  • profits backed by cash
  • short-term liquidity improved
  • no new shares issued
  • gross margin widened
  • assets working harder

Repair signals

  • Gross margin 48.9% → 62.2%

Trade setup

ATR% 2.1% $1.05 a day · 2×ATR $48.11
RS 74 / 99 vs the universe
Trend 7 / 8 150-day under the 200-day
Relative volume 1.1× vs 50-day average
Up/down volume 2.05 50 sessions
Implied move — no option chain · report Nov 4, 2026
Trend template · 7 of 8
  • 150-day average above the 200-day: fails

Screen verdict

1 of 3 screens
  • Repair to Leader in mixed conditions
    • Fell 41% within the year
    • 55% above the low
    • Trend 7/8, above its 50-day, 200-day rising
    • F-score 8/9
    • Cheaper than 57%
    • Altman Z 4.08 (low risk)
    • Relative strength turning up (+22 pts, 3m vs 12m)
    • RS 74

Warning signs

none flagged
  • No restatement or impairment
  • Equity positive
  • Interest covered
  • No material dilution
  • Profits tracking cash
  • Margins and revenue not shrinking

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $2.1B +6% on FY2024
$0 $2.5B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $1.9B FY2021 · $2.3B FY2022 · $2.1B FY2023 · $2.0B FY2024 · $2.0B FY2025 · $2.1B
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $424.9M +408% on FY2024
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $359.2M FY2021 · $512.6M FY2022 · $423.2M FY2023 · $341.3M FY2024 · $83.6M FY2025 · $424.9M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $453.3M -10% on FY2024
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $325.0M FY2021 · $449.1M FY2022 · $586.0M FY2023 · $309.7M FY2024 · $506.4M FY2025 · $453.3M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 62%
  • Net 20%
  • Free cash 22%
0% 100% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Gross 66% · Net 19% · Free cash 17% FY2021 · Gross 64% · Net 23% · Free cash 20% FY2022 · Gross 65% · Net 20% · Free cash 27% FY2023 · Gross 63% · Net 17% · Free cash 16% FY2024 · Gross 49% · Net 4% · Free cash 26% FY2025 · Gross 62% · Net 20% · Free cash 22%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $815.4M net debt
  • Cash
  • Long-term debt
$0 $2B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $598.0M · Long-term debt $1.9B FY2021 · Cash $880.5M · Long-term debt $1.1B FY2022 · Cash $730.7M · Long-term debt $1.5B FY2023 · Cash $668.1M · Long-term debt $921.8M FY2024 · Cash $663.6M · Long-term debt $839.7M FY2025 · Cash $839.0M · Long-term debt $1.7B
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 216.92m -4.9% since FY2020
228.20m 216.92m FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · 227.99m FY2021 · 227.07m FY2022 · 227.72m FY2023 · 228.20m FY2024 · 222.29m FY2025 · 216.92m
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $1.9B $2.3B $2.1B $2.0B $2.0B $2.1B
Gross margin 66% 64% 65% 63% 49% 62%
Operating income $386.4M $630.1M $531.5M $409.9M $97.7M $465.9M
Net income $359.2M $512.6M $423.2M $341.3M $83.6M $424.9M
Net margin 19% 23% 20% 17% 4% 20%
Earnings per share $1.53 $2.21 $1.84 $1.48 $0.37 $1.94
Free cash flow $325.0M $449.1M $586.0M $309.7M $506.4M $453.3M
Free cash margin 17% 20% 27% 16% 26% 22%
Cash $598.0M $880.5M $730.7M $668.1M $663.6M $839.0M
Long-term debt $1.9B $1.1B $1.5B $921.8M $839.7M $1.7B
Shareholders' equity $2.8B $3.1B $3.5B $3.8B $3.6B $3.8B
Shares outstanding 227.99m 227.07m 227.72m 228.20m 222.29m 216.92m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Mar 20, 2026 Annual ↗ Dec 31, 2025 79d
Mar 31, 2025 Annual ↗ Dec 31, 2024 90d
Mar 11, 2024 Annual ↗ Dec 31, 2023 71d
Mar 13, 2023 Annual ↗ Dec 31, 2022 72d
Mar 14, 2022 Annual ↗ Dec 31, 2021 73d
Mar 5, 2021 Annual ↗ Dec 31, 2020 64d
Mar 2, 2020 Annual ↗ Dec 31, 2019 62d
Mar 6, 2019 Annual ↗ Dec 31, 2018 65d
Mar 6, 2018 Annual ↗ Dec 31, 2017 65d
Mar 6, 2017 Annual ↗ Dec 31, 2016 65d
Feb 29, 2016 Annual ↗ Dec 31, 2015 60d
Mar 2, 2015 Annual ↗ Dec 31, 2014 61d

Current reports

FiledDisclosed
Oct 23, 2026 Foreign issuer report ↗
Sep 9, 2026 Foreign issuer report ↗
Aug 7, 2026 Foreign issuer report ↗
Aug 7, 2026 Foreign issuer report ↗
Aug 7, 2026 Foreign issuer report ↗
May 8, 2026 Foreign issuer report ↗
May 8, 2026 Foreign issuer report ↗
May 1, 2026 Foreign issuer report ↗
Feb 6, 2026 Foreign issuer report ↗
Dec 22, 2025 Foreign issuer report ↗
Nov 6, 2025 Foreign issuer report ↗
Nov 6, 2025 Foreign issuer report ↗